Matrix metalloproteinases in human spontaneous intracerebral hemorrhage: An update

Cerebrovascular Diseases

Volumn 34, Issue 4, 2012, Pages 249-262

  Florczak Rzepka, M ^a,b   Grond Ginsbach, C ^b   Montaner, J ^d   Steiner, T ^b,c  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Brain edema; Hematoma growth; Hemorrhagic stroke; Inflammation; Matrix metalloproteinases; Spontaneous intracerebral hemorrhage

Indexed keywords

ADAM PROTEIN; BATIMASTAT; BB 1101; BB 2983; COLLAGENASE 3; DIMETHYL SULFOXIDE; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; IW 499; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MEMANTINE; REACTIVE OXYGEN METABOLITE; SCLEROPROTEIN; STEROID; STROMELYSIN 3; TETRACYCLINE DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UROKINASE; VALPROIC ACID;

BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; HEMATOMA; HUMAN; INFORMATION RETRIEVAL; MOLECULAR BIOLOGY; NERVOUS SYSTEM INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SPONTANEOUS INTRACEREBRAL HEMORRHAGE;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN INJURIES; CEREBRAL HEMORRHAGE; HUMANS; INFLAMMATION; MATRIX METALLOPROTEINASES; STROKE;

EID: 84867220944     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000341686     Document Type: Review

References (65)

1. Sacco S, Marini C, Toni D, Olivieri L, Carolei A: Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry. Stroke 2009; 40: 394-399.
2. Morgenstern L, Hemphill J III, Anderson C, Becker K, Broderick JP, Connolly ES Jr, Greenberg SM, Huang JN, MacDonald RL, Messé SR, Mitchell PH, Selim M, Tamargo RJ; American Heart Association Stroke Council and Council on Cardiovascular Nursing: Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010; 41: 2108-2129.
3. Steiner T, Kaste M, Forsting M, Mendelow D, Kwiecinski H, Szikora I, Juvela S, Marchel A, Chapot R, Cognard C, Unterberg A, Hacke W: Recommendations for the management of intracranial haemorrhage. I. Spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis 2006; 22: 294-316. (Pubitemid 44338094)
4. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T; FAST Trial Investigators: Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358: 2127-2137. (Pubitemid 351679599)
5. Bogousslavsky J, Piechowski-Jozwiak B: Prothrombotic recombinant activated factor VII in intracerebral haemorrhage: FAST but not focused? Lancet Neurol 2008; 7: 670-672. (Pubitemid 351965505)
6. Mayer SA, Davis SM, Skolnick BE, Brun NC, Begtrup K, Broderick JP, Diringer MN, Steiner T; FAST trial investigators: Can a subset of intracerebral hemorrhage patients benefit from hemostatic therapy with recombinant activated factor VII? Stroke 2009;40:833-840.
7. Xi G, Keep RF, Hoff JT: Pathophysiology of brain edema formation. Neurosurg Clin N Am 2002; 13: 371-383.
8. Brott T, Broderick J, Kothari R, Barsan W, Tomsick T, Sauerbeck L, Spilker J, Duldner J, Khoury J: Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997; 28: 1-5. (Pubitemid 27039454)
9. Inaji M, Tomita H, Tone O, Tamaki M, Suzuki R, Ohno K: Chronological changes of perihematomal edema of human intracerebral hematoma. Acta Neurochir Supplement 2003; 86: 445-448.
10. Gebel J Jr, Jauch E, Brott T, Khoury J, Sauerbeck L, Salisbury S, Spilker J, Tomsick TA, Duldner J, Broderick JP: Relative edema volume is a predictor of outcome in patients with hyperacute spontaneous intracerebral hemorrhage. Stroke 2002; 33: 2636.
11. Michel-Monigadon D, Bonny C, Hirt L: C-Jun N-Terminal kinase pathway inhibition in intracerebral hemorrhage. Cerebrovasc Dis 2010; 29: 564-570.
12. Kuittinen O: Matrix metalloproteinase-2 (MMP-2) and-9 (MMP-9) in hematological malignancies. Acta Univ Oul D 712, 2003, pp 1-82.
13. Overall CM, López-Otín C: Strategies for MMP inhibition in cancer: Innovations for the post-Trial era. Nat Rev Cancer 2002; 2: 657-672. (Pubitemid 37328917)
14. Yong V: Metalloproteinases: Mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 2005; 6: 931-944. (Pubitemid 41753087)
15. Cauwe B, Opdenakker G: Intracellular substrate cleavage: A novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit Rev Biochem Mol Biol 2010; 45: 351-423.
16. Mannello F, Medda V: Nuclear localization of matrix metalloproteinases. Prog Histochem Cytochem 2012; 47: 27-58.
17. Mun-Bryce S, Rosenberg G: Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab 1998; 18: 1163-1172. (Pubitemid 28509829)
18. Makowski G, Ramsby M: Binding of latent matrix metalloproteinase 9 to fibrin: Activation via a plasmin-dependent pathway. Inflammation 1998; 22: 287-305. (Pubitemid 28234157)
19. Pei D, Weiss SJ: Transmembrane-deletion mutants of the membrane-Type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity. J Biol Chem 1996; 271: 9135-9140.
20. Yana I, Weiss SJ: Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases. Mol Biol Cell 2000; 11: 2387-2401. (Pubitemid 30489922)
21. Overall CM, Kleifeld O: Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 2006; 94: 941-946.
22. Murphy G, Stanton H, Cowell S, Butler G, Knäuper V, Atkinson S, Gavrilovic J: Mechanisms for pro matrix metalloproteinase activation. APMIS 1999; 107: 38-44. (Pubitemid 29133521)
23. Fu X, Kassim SY, Parks WC, Heinecke JW: Hypochlorous acid generated by myeloperoxidase modifies adjacent tryptophan and glycine residues in the catalytic domain of matrix metalloproteinase-7 (matrilysin): An oxidative mechanism for restraining proteolytic activity during inflammation. J Biol Chem 2003; 278: 28403-28409. (Pubitemid 36935741)
24. Yong V: The potential use of MMP inhibitors to treat CNS diseases. Expert Opin Investig Drugs 1999; 8: 255-268. (Pubitemid 29106357)
25. Peters DG, Kassam A, St Jean PL, Yonas H, Ferrell RE: Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. Stroke 1999; 30: 2612-2616.
26. Wells JEA, Biernaskie J, Szymanska A, Larsen PH, Yong VW, Corbett D: Matrix metalloproteinase (MMP)-12 expression has a negative impact on sensorimotor function following intracerebral haemorrhage in mice. Eur J Neurosci 2005; 21: 187-196. (Pubitemid 40193887)
27. Cunningham L, Wetzel M, Rosenberg G: Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 2005; 50: 329-339. (Pubitemid 40780839)
28. Wallace J, Alexander S, Estrada E, Hines C, Cunningham LA, Rosenberg GA: Tissue inhibitor of metalloproteinase-3 is associated with neuronal death in reperfusion injury. J Cereb Blood Flow Metab 2002; 22: 1303-1310. (Pubitemid 35285087)
29. Aronowski J, Zhao X: Molecular pathophysiology of cerebral hemorrhage: Secondary brain injury. Stroke 2011; 42: 1781-1786.
30. Zhao X, Sun G, Zhang J, Strong R, Dash PK, Kan YW, Grotta JC, Aronowski J: Transcription factor Nrf2 protects the brain from damage produced by intracerebral hemorrhage. Stroke 2007; 38: 3280-3286. (Pubitemid 350175749)
31. Zhao X, Sun G, Zhang J, Strong R, Song W, Gonzales N, Grotta JC, Aronowski J: Hematoma resolution as a target for intracerebral hemorrhage treatment: Role for peroxisome proliferator-activated receptor in microglia/ macrophages. Ann Neurol 2007; 61: 352-362. (Pubitemid 46676735)
32. Zhao X, Zhang Y, Strong R, Grotta JC, Aronowski J: 15d-Prostaglandin J2 activates peroxisome proliferator-activated receptorgamma, promotes expression of catalase, and reduces inflammation, behavioral dysfunction, and neuronal loss after intracerebral hemorrhage in rats. J Cereb Blood Flow Metab 2006; 26: 811-820.
33. Aronowski J, Hall C: New horizons for primary intracerebral hemorrhage treatment: Experience from preclinical studies. Neurol Res 2005; 27: 268-279. (Pubitemid 40523798)
34. Nishino A, Suzuki M, Ohtani H, Motohashi O, Umezawa K, Nagura H, Yoshimoto T: Thrombin may contribute to the pathophysiology of central nervous system injury. J Neurotrauma 1993; 10: 167-179. (Pubitemid 23209482)
35. Feuerstein GZ, Wang X, Barone FC: The role of cytokines in the neuropathology of stroke and neurotrauma. Neuroimmunomodulation 1998; 5: 143-159. (Pubitemid 28417026)
36. Tejima E, Zhao B-Q, Tsuji K, Rosell A, van Leyen K, Gonzalez RG, Montaner J, Wang X, Lo EH: Astrocytic induction of matrix metalloproteinase-9 and edema in brain hemorrhage. J Cereb Blood Flow Metab 2007; 27: 460-468.
37. Abbott NJ, Rönnbäck L, Hansson E: Astrocyte-Endothelial interactions at the bloodbrain barrier. Nat Rev Neurosci 2006; 7: 41-53.
38. Power C, Henry S, Del Bigio M, Larsen PH, Corbett D, Imai Y, Yong VW, Peeling J: Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann Neurol 2003; 53: 731-742. (Pubitemid 36622510)
39. Mun-Bryce S, Wilkerson A, Pacheco B, Zhang T, Rai S, Wang Y, Okada Y: Depressed cortical excitability and elevated matrix metalloproteinases in remote brain regions following intracerebral hemorrhage. Brain Res 2004; 1026: 227-234. (Pubitemid 39361551)
40. Dziedzic T: Clinical significance of acute phase reaction in stroke patients. Front Biosci 2008; 13: 2922-2927. (Pubitemid 351589209)
41. Rosenberg GA, Estrada EY, Mobashery S: Effect of synthetic matrix metalloproteinase inhibitors on lipopolysaccharide-induced blood-brain barrier opening in rodents: Differences in response based on strains and solvents. Brain Res 2007; 1133: 186-192. (Pubitemid 46123248)
42. Castellanos M, Leira R, Serena J, Blanco M, Pedraza S, Castillo J, Dávalos A: Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 2004; 35: 1671-1676. (Pubitemid 38823645)
43. Abilleira S, Montaner J, Molina CA, Monasterio J, Castillo J, Alvarez-Sabín J: Matrix metalloproteinase-9 concentration after spontaneous intracerebral hemorrhage. J Neurosurg 2003; 99: 65-70. (Pubitemid 36753878)
44. Silva Y, Leira R, Tejada J, Lainez JM, Castillo J, Dávalos A; Stroke Project, Cerebrovascular Diseases Group of the Spanish Neurological Society: Molecular signatures of vascular injury are associated with early growth of intracerebral hemorrhage. Stroke 2005; 36: 86-91. (Pubitemid 40054180)
45. Rosell A, Ortega-Aznar A, Alvarez-Sabín J, Fernández- Cadenas I, Ribó M, Molina CA, Lo EH, Montaner J: Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 2006; 37: 1399-1406. (Pubitemid 44305716)
46. Wu H, Zhang Z, Hu X, Zhao R, Song Y, Ban X, Qi J, Wang J: Dynamic changes of inflammatory markers in brain after hemorrhagic stroke in humans: A postmortem study. Brain Res 2010; 1342: 111-117.
47. Wu C, Huang F, Wang K, Huang S, Yang RL, Li HZ, Lei HX, Lin JS, Wang JM, Yan XH: Expression of matrix metalloproteinase MMP-9 in the plasma and hematoma fluid of intracerebral hemorrhage patients (in Chinese). Zhonghua Yi Xue Za Zhi 2008; 88: 174-176. (Pubitemid 351459968)
48. Alvarez-Sabín J, Delgado P, Abilleira S, Molina CA, Arenillas J, Ribó M, Santamarina E, Quintana M, Monasterio J, Montaner J: Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: Relationship to clinical and radiological outcome. Stroke 2004; 35: 1316-1322. (Pubitemid 38697450)
49. Castellazzi M, Tamborino C, De Santis G, Garofano F, Lupato A, Ramponi V, Trentini A, Casetta I, Bellini T, Fainardi E: Timing of serum active MMP-9 and MMP-2 levels in acute and subacute phases after spontaneous intracerebral hemorrhage. Acta Neurochir Suppl 2010; 106: 137-140.
50. Yamani MH, Starling RC, Cook DJ, Tuzcu EM, Abdo A, Paul P, Powell K, Ratliff NB, Yu Y, McCarthy PM, Young JB: Donor spontaneous intracerebral hemorrhage is associated with systemic activation of matrix metalloproteinase-2 and matrix metalloproteinase-9 and subsequent development of coronary vasculopathy in the heart transplant recipient. Circulation 2003; 108: 1724-1728. (Pubitemid 37243661)
51. Lee J-M, Yin K, Hsin I, Chen S, Fryer JD, Holtzman DM, Hsu CY, Xu J: Matrix metalloproteinase-9 in cerebral-amyloid-angiopathy-related hemorrhage. J Neurol Sci 2005; 229-230: 249-254. (Pubitemid 40341590)
52. Hernandez-Guillamon M, Martinez-Saez E, Delgado P, Domingues-Montanari S, Boada C, Penalba A, Boada M, Pagola J, Maisterra O, Rodriguez-Luna D, Molina CA, Rovira A, Alvarez-Sabin J, Ortega-Aznar A, Montaner J: MMP-2/MMP-9 plasma level and brain expression in cerebral amyloid angiopathy-associated hemorrhagic stroke. Brain Pathol 2012; 22: 133-141.
53. Fujimura M, Watanabe M, Narisawa A, Shimizu H, Tominaga T: Increased expression of serum matrix metalloproteinase-9 in patients with moyamoya disease. Surg Neurol 2009; 72: 476-480, discussion 480.
54. Frösen J, Tulamo R, Paetau A, Laaksamo E, Korja M, Laakso A, Niemelä M, Hernesniemi J: Saccular intracranial aneurysm: Pathology and mechanisms. Acta Neuropathol 2012; 123: 773-786.
55. Hasan DM, Mahaney KB, Brown RD Jr, Meissner I, Piepgras DG, Huston J, Capuano AW, Torner JC; International Study of Unruptured Intracranial Aneurysms Investigators: Aspirin as a promising agent for decreasing incidence of cerebral aneurysm rupture. Stroke 2011; 42: 3156-3162.
56. Chou SH-Y, Feske SK, Simmons SL, Konigsberg RG, Orzell SC, Marckmann A, Bourget G, Bauer DJ, De Jager PL, Du R, Arai K, Lo EH, Ning MM: Elevated peripheral neutrophils and matrix metalloproteinase 9 as biomarkers of functional outcome following subarachnoid hemorrhage. Transl Stroke Res 2011; 2: 600-607.
57. Sarrafzadeh A, Copin J-C, Bengualid DJ, Turck N, Vajkoczy P, Bijlenga P, Schaller K, Gasche Y: Matrix metalloproteinase-9 concentration in the cerebral extracellular fluid of patients during the acute phase of aneurismal subarachnoid hemorrhage. Neurol Res 2012; 34: 455-461.
58. Wang J, Tsirka S: Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage. Brain 2005; 128: 1622-1633. (Pubitemid 41373681)
59. Lee C, Xue Z, Zhu Y, Yang G, Young W: Matrix metalloproteinase-9 inhibition attenuates vascular endothelial growth factorinduced intracerebral hemorrhage. Stroke 2007; 38: 2563-2568. (Pubitemid 47329638)
60. Grossetete M, Rosenberg G: Matrix metalloproteinase inhibition facilitates cell death in intracerebral hemorrhage in mouse. J Cereb Blood Flow Metab 2007; 28: 752-763.
61. Lee S, Chu K, Jung K, Kim J, Kim EH, Kim SJ, Sinn DI, Ko SY, Kim M, Roh JK: Memantine reduces hematoma expansion in experimental intracerebral hemorrhage, resulting in functional improvement. J Cereb Blood Flow Metab 2005; 26: 536-544.
62. Sinn D-I, Kim S-J, Chu K, Jung KH, Lee ST, Song EC, Kim JM, Park DK, Kun Lee S, Kim M, Roh JK: Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation. Neurobiol Dis 2007; 26: 464-472. (Pubitemid 46578295)
63. Wang X, Jung J, Asahi M, Chwang W, Russo L, Moskowitz MA, Dixon CE, Fini ME, Lo EH: Effects of matrix metalloproteinase-9 gene knock-out on morphological and motor outcomes after traumatic brain injury. J Neurosci 2000; 20: 7037-7042.
64. Tang J, Liu J, Zhou C, Alexander JS, Nanda A, Granger DN, Zhang JH: MMP-9 deficiency enhances collagenase-induced intracerebral hemorrhage and brain injury in mutant mice. J Cereb Blood Flow Metab 2004; 24: 1133-1145. (Pubitemid 39332152)
65. Zlokovic BV: Remodeling after stroke. Nat Med 2006; 12: 390-391.